论文部分内容阅读
目的:探讨左炔诺孕酮宫内缓释系统预防乳腺癌患者服用他莫西芬所致子宫内膜息肉效果。方法:随诊103例围绝经期及绝经后服用他莫西芬妇女随机分成2组,其中55例在服用他莫西芬前放置曼月乐环,48例作为对照组。治疗前及他莫西芬治疗12个月后分别行经阴道超声检查子宫内膜厚度及宫腔镜检查子宫内膜病理。结果:放置曼月乐环组发生子宫内膜息肉风险明显低于对照组(1.8%∶15.5%,P=0.02),发生子宫黏膜下肌瘤风险两组间差异无统计学意义(1.8%∶3.4%,P=1.0)。结论:左炔诺孕酮宫内缓释系统降低乳腺癌患者服用他莫西芬所致子宫内膜息肉的发生。
Objective: To investigate the effect of levonorgestrel-releasing intrauterine system in preventing endometrial polyps induced by tamoxifen in breast cancer patients. Methods: 103 cases of climacteric menopausal women and menopausal women taking tamoxifen were randomly divided into two groups, of which 55 cases were placed before the tamoxifen placed Mirena ring, 48 cases as a control group. Before treatment and 12 months after tamoxifen treatment, transvaginal ultrasonography was performed to detect the thickness of endometrium and hysteroscopy to detect endometrial pathology. Results: The risk of endometrial polyps in Mirena group was significantly lower than that in control group (1.8%: 15.5%, P = 0.02). The risk of uterine submucous myoma was not significantly different between the two groups (1.8% 3.4%, P = 1.0). CONCLUSIONS: Levonorgestrel-releasing intrauterine system reduces the incidence of endometrial polyps induced by tamoxifen in breast cancer patients.